Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors.

Abstract

Solid tumors, especially desmoplastic tumors, are characterized by a dense fibrotic stroma composed of abundant cancer-associated fibroblasts and excessive extracellular matrix. These physical barriers seriously compromise drug delivery to tumor cells, leading to suboptimal treatment efficacy and resistance to current tumor-centric therapeutics. The need to overcome these problems has driven extensive investigations and sparked the flourish of anti-stromal therapy, particularly in the field of nanomedicines. In this paper, we firstly review the major components of the tumor stroma and discuss their impact on drug delivery. Then, according to the different stromal targets, we summarize the current status of anti-stromal therapy and highlight recent advances in anti-stromal nanomedicines. We further examine the potential of nano-enabled anti-stromal therapy to enhance the anti-tumor efficacy of other therapeutic modalities, including chemotherapy, immunotherapy, phototherapy and radiotherapy. Finally, the potential concerns and future developments of anti-stromal nanomedicines are discussed.

• Authors: Xuexiang Han, Ying Xu, Marzieh Geranpayehvaghei, Gregory J Anderson, Yiye Li, Guangjun Nie
• Journal: Biomaterials (Biomaterials) Vol. 232 Pg. 119745 (02 2020) ISSN: 1878-5905 [Electronic] Netherlands
• PMID: 31918228 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2020 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents

Topics

• Antineoplastic Agents (therapeutic use)
• Drug Delivery Systems
• Humans
• Immunotherapy
• Nanomedicine
• Neoplasms (drug therapy)